MAPT and Alzheimer disease: In this context, the pathological convergence between tau and Ab at AD synaptic mitochondria may help to explain why the diseased A- or tau-modifying strategies have not singularly given promising results and suggest potential new pathway(s) and target(s) [153] for a combined, more efficient therapeutic intervention of early synaptic dysfunction in AD.